Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Assets (2016 - 2025)

Ptc Therapeutics has reported Assets over the past 14 years, most recently at $2.9 billion for Q4 2025.

  • Quarterly results put Assets at $2.9 billion for Q4 2025, up 70.01% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (up 70.01% YoY), and the annual figure for FY2025 was $2.9 billion, up 70.01%.
  • Assets for Q4 2025 was $2.9 billion at Ptc Therapeutics, up from $2.6 billion in the prior quarter.
  • Over the last five years, Assets for PTCT hit a ceiling of $2.9 billion in Q4 2025 and a floor of $1.3 billion in Q3 2023.
  • Median Assets over the past 5 years was $1.9 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Assets: decreased 25.83% in 2023 and later soared 70.01% in 2025.
  • Ptc Therapeutics' Assets stood at $1.9 billion in 2021, then dropped by 11.99% to $1.7 billion in 2022, then rose by 11.14% to $1.9 billion in 2023, then fell by 10.06% to $1.7 billion in 2024, then soared by 70.01% to $2.9 billion in 2025.
  • The last three reported values for Assets were $2.9 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.